Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Current Deferred Revenue (2020 - 2024)

SAB Biotherapeutics' Current Deferred Revenue history spans 4 years, with the latest figure at $114698.0 for Q3 2024.

  • For Q3 2024, Current Deferred Revenue fell 92.95% year-over-year to $114698.0; the TTM value through Sep 2024 reached $114698.0, down 92.95%, while the annual FY2023 figure was $1.3 million, N/A changed from the prior year.
  • Current Deferred Revenue reached $114698.0 in Q3 2024 per SABSW's latest filing, roughly flat from $114698.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $2.9 million in Q1 2023 to a low of $100000.0 in Q4 2020.
  • Average Current Deferred Revenue over 4 years is $1.1 million, with a median of $377835.0 recorded in 2024.
  • Peak YoY movement for Current Deferred Revenue: changed 0.0% in 2021, then crashed 96.04% in 2024.
  • A 4-year view of Current Deferred Revenue shows it stood at $100000.0 in 2020, then changed by 0.0% to $100000.0 in 2021, then skyrocketed by 1222.41% to $1.3 million in 2023, then crashed by 91.33% to $114698.0 in 2024.
  • Per Business Quant, the three most recent readings for SABSW's Current Deferred Revenue are $114698.0 (Q3 2024), $114698.0 (Q2 2024), and $377835.0 (Q1 2024).